China’s Mindray Refutes Merit Of Report That Sent Stock Plummeting
This article was originally published in The Gray Sheet
Executive Summary
Mindray stock recovers from freefall after allegations that China’s leading medical device company overstated its earnings and engaged in fraudulent accounting practices.
You may also be interested in...
Mindray Doubles Patient Monitor Biz, Builds U.S. Presence With Acquisition
China-based Mindray Medical will supply components for Datascope's patient monitoring business unit after acquiring the subsidiary for $202 million in a deal announced March 11
EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: